Wexford Laboratories now has available one of the most commonly used antiemetics for the treatment of Nausea and Vomiting: Ondansetron 4 mg/2 mL Injectable Solution, a product highly utilized by Oncologists and Surgeons.
If you want to discover how our New Formulation can revitalize your product portfolio and help you stay at the forefront of trends in highly demanded and profitable products, we invite you to keep reading.
Why should you have Ondansetron 4 mg/2 mL Injectable Solution in your product portfolio?
Ondansetron 4 mg/2 mL Injectable Solution is a widely used medication in both hospital and outpatient settings to prevent and treat nausea and vomiting induced by chemotherapy, radiotherapy, and surgery. This capability makes it a crucial component in managing patient comfort during intensive treatments and surgical procedures.
Ondansetron is one of the most prescribed antiemetics worldwide due to its efficacy and safety, making it an ideal option to bring an innovative twist to your product portfolio by including formulations that have high turnover and are projected to increase in use.
Advantages of Including Ondansetron 4 mg/2 mL Injectable Solution in Your Product Portfolio
- High Demand in the Healthcare Market: The need for effective antiemetic medications continues to grow, especially with the increasing number of cancer cases requiring chemotherapy. This ensures a constant demand for Ondansetron. The global antiemetic drugs market size was valued at USD 7.49 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.98% from 2024 to 2030.
- Perfect Complement for Complex Treatment Protocols: Ondansetron can be part of standard protocols in oncological and perioperative treatments, expanding business opportunities by offering an essential product in these contexts.
- Ease of Market Integration: Being a well-established and well-known medication, Ondansetron 4 mg/2 mL Injectable Solution can be easily integrated into pharmaceutical laboratories’ product offerings, facilitating its promotion and sale.
- Safety Profile: With a good safety profile, Ondansetron is well-tolerated by most patients, presenting few adverse side effects compared to other antiemetics.
- Reputation and Trust: Finally, it is worth noting that with over 30 years of experience, Wexford Laboratories has established a high level of trust and reputation among hospitals, pharmacies, healthcare professionals, and end consumers throughout much of Latin America. By being manufactured by us, your product will have a competitive edge over less prominent manufacturers’ brands, giving your product a distinctive and solid image in the market.
Competitive Price Advantages
- Cost-Effectiveness: Ondansetron, despite being an advanced option, has a good cost-benefit ratio. The costs associated with its production and distribution are competitive, allowing us to offer you attractive prices. If you want a reference quote, contact us HERE.
- Access to Public and Private Health Programs: Thanks to its efficacy and low cost, Ondansetron 4 mg/2 mL Injectable Solution can be part of public and private health programs, increasing potential sales volume.
- Strategic Market Positioning: Having Ondansetron 4 mg/2 mL Injectable Solution in the portfolio can allow laboratories to strategically position themselves in the high-turnover generic drug market.
Ondansetron 4 mg/2 mL Injectable Solution not only represents a significant advancement in the management of nausea and vomiting but also offers pharmaceutical laboratories a solid and sustainable business opportunity. Its integration into the product portfolio can be a strategic step that will benefit both healthcare providers and patients while ensuring a positive impact on the financial outcomes of pharmaceutical companies. With its proven efficacy and competitive advantages, Ondansetron 4 mg/2 mL Injectable Solution is undoubtedly a valuable investment for any pharmaceutical portfolio.
Contact us and start this great project with Wexford Laboratories, where we offer products with the highest quality standards and support throughout the product registration process. Our experience in pharmaceutical product contract manufacturing ensures that our partners benefit from a product of excellence that meets market expectations and patient needs. Partner with us and discover how we can help you achieve your business goals with a reliable, effective, and high-turnover product.
- Ashour, A. M. (2023). The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1310455
- Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., Eng, C., Feyer, P. C., Jordan, K., Noonan, K., Sparacio, D., Somerfield, M. R., & Lyman, G. H. (2017). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. Journal of Clinical Oncology, 35(28), 3240–3261. https://doi.org/10.1200/jco.2017.74.4789
- Öztürk, M. A. (2017). An overview of the latest ASCO recommendations about antiemetic prophylaxis for treatment-related nausea and vomiting. Journal of Oncological Sciences, 3(3), 99–101. https://doi.org/10.1016/j.jons.2017.09.001
- Weibel, S., Rücker, G., Eberhart, L. H., Pace, N. L., Hartl, H. M., Jordan, O. L., Mayer, D., Riemer, M., Schaefer, M. S., Raj, D., Backhaus, I., Helf, A., Schlesinger, T., Kienbaum, P., & Kranke, P. (2020). Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Library, 2020(11). https://doi.org/10.1002/14651858.cd012859.pub2
- Antiemetics Drugs Market Size, Share & Trends Analysis Report by drug type (Serotonin-receptor antagonists, Dopamine receptor Antagonists), by application, by end-use, by region, and segment Forecasts, 2024 – 2030. (n.d.). https://www.grandviewresearch.com/industry-analysis/antiemetics-drugs-market-report#:~:text=Antiemetics%20Drugs%20Market%20Size%20%26%20Trends,such%20as%20vomiting%20and%20nausea
- Essential Medicines (EML). (2023b, July 26). WHO Model List of Essential Medicines – 23rd list, 2023. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
Ondansetron Uses, Dosage & Side Effects. (n.d.). Drugs.com. https://www.drugs.com/ondansetron.html
To learn more, find us at https://www.wexlabs.com/ and follow us on Instagram @wexfordlabs. We are on LinkedIn as Wexford Laboratories. Also, like our Facebook page @WexfordLaboratories.
